Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Insight Into Molecular Determinants of T3 vs T4 Recognition From Mutations in Thyroid Hormone Receptor α and β.

Wejaphikul K, Groeneweg S, Hilhorst-Hofstee Y, Chatterjee VK, Peeters RP, Meima ME, Visser WE.

J Clin Endocrinol Metab. 2019 Aug 1;104(8):3491-3500. doi: 10.1210/jc.2018-02794.

2.

Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves' orbitopathy: a case series.

Roos JCP, Moran C, Chatterjee VK, Jones J, Coles A, Murthy R.

Eye (Lond). 2019 Feb;33(2):223-229. doi: 10.1038/s41433-018-0282-1. Epub 2018 Nov 29.

PMID:
30498266
3.

Role of Leucine 341 in Thyroid Hormone Receptor Beta Revealed by a Novel Mutation Causing Thyroid Hormone Resistance.

Wejaphikul K, Groeneweg S, Dejkhamron P, Unachak K, Visser WE, Chatterjee VK, Visser TJ, Meima ME, Peeters RP.

Thyroid. 2018 Nov 27. doi: 10.1089/thy.2018.0146. [Epub ahead of print]

PMID:
30362879
4.

Homozygous loss-of-function mutations in SLC26A7 cause goitrous congenital hypothyroidism.

Cangul H, Liao XH, Schoenmakers E, Kero J, Barone S, Srichomkwun P, Iwayama H, Serra EG, Saglam H, Eren E, Tarim O, Nicholas AK, Zvetkova I, Anderson CA, Frankl FEK, Boelaert K, Ojaniemi M, Jääskeläinen J, Patyra K, Löf C, Williams ED; UK10K Consortium, Soleimani M, Barrett T, Maher ER, Chatterjee VK, Refetoff S, Schoenmakers N.

JCI Insight. 2018 Oct 18;3(20). pii: 99631. doi: 10.1172/jci.insight.99631.

5.

Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab.

Casey RT, Giger O, Seetho I, Marker A, Pitfield D, Boyle LH, Gurnell M, Shaw A, Tischkowitz M, Maher ER, Chatterjee VK, Janowitz T, Mells G, Corrie P, Challis BG.

Semin Oncol. 2018 Jun;45(3):151-155. doi: 10.1053/j.seminoncol.2018.06.001. Epub 2018 Jun 21.

6.

Adult-onset hyperinsulinaemic hypoglycaemia in clinical practice: diagnosis, aetiology and management.

Challis BG, Powlson AS, Casey RT, Pearson C, Lam BY, Ma M, Pitfield D, Yeo GSH, Godfrey E, Cheow HK, Chatterjee VK, Carroll NR, Shaw A, Buscombe JR, Simpson HL.

Endocr Connect. 2017 Oct;6(7):540-548. doi: 10.1530/EC-17-0076. Epub 2017 Aug 7.

7.

Digenic DUOX1 and DUOX2 Mutations in Cases With Congenital Hypothyroidism.

Aycan Z, Cangul H, Muzza M, Bas VN, Fugazzola L, Chatterjee VK, Persani L, Schoenmakers N.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3085-3090. doi: 10.1210/jc.2017-00529.

8.

Comprehensive Screening of Eight Known Causative Genes in Congenital Hypothyroidism With Gland-in-Situ.

Nicholas AK, Serra EG, Cangul H, Alyaarubi S, Ullah I, Schoenmakers E, Deeb A, Habeb AM, Almaghamsi M, Peters C, Nathwani N, Aycan Z, Saglam H, Bober E, Dattani M, Shenoy S, Murray PG, Babiker A, Willemsen R, Thankamony A, Lyons G, Irwin R, Padidela R, Tharian K, Davies JH, Puthi V, Park SM, Massoud AF, Gregory JW, Albanese A, Pease-Gevers E, Martin H, Brugger K, Maher ER, Chatterjee VK, Anderson CA, Schoenmakers N.

J Clin Endocrinol Metab. 2016 Dec;101(12):4521-4531. Epub 2016 Aug 15.

9.

Molecular spectrum of TSHβ subunit gene defects in central hypothyroidism in the UK and Ireland.

Nicholas AK, Jaleel S, Lyons G, Schoenmakers E, Dattani MT, Crowne E, Bernhard B, Kirk J, Roche EF, Chatterjee VK, Schoenmakers N.

Clin Endocrinol (Oxf). 2017 Mar;86(3):410-418. doi: 10.1111/cen.13149. Epub 2016 Aug 4.

10.

The Hypercoagulable state in Hyperthyroidism is mediated via the Thyroid Hormone β Receptor pathway.

Elbers LP, Moran C, Gerdes VE, van Zaane B, Meijers J, Endert E, Lyons G, Chatterjee VK, Bisschop PH, Fliers E.

Eur J Endocrinol. 2016 Mar 9. pii: EJE-15-1249. [Epub ahead of print]

PMID:
26961801
11.

Mild cold effects on hunger, food intake, satiety and skin temperature in humans.

Langeveld M, Tan CY, Soeters MR, Virtue S, Ambler GK, Watson LP, Murgatroyd PR, Chatterjee VK, Vidal-Puig A.

Endocr Connect. 2016 Mar;5(2):65-73. doi: 10.1530/EC-16-0004. Epub 2016 Feb 10.

12.

A Novel Thyrotropin-Releasing Hormone Receptor Missense Mutation (P81R) in Central Congenital Hypothyroidism.

Koulouri O, Nicholas AK, Schoenmakers E, Mokrosinski J, Lane F, Cole T, Kirk J, Farooqi IS, Chatterjee VK, Gurnell M, Schoenmakers N.

J Clin Endocrinol Metab. 2016 Mar;101(3):847-51. doi: 10.1210/jc.2015-3916. Epub 2016 Jan 6.

13.

Recent advances in central congenital hypothyroidism.

Schoenmakers N, Alatzoglou KS, Chatterjee VK, Dattani MT.

J Endocrinol. 2015 Dec;227(3):R51-71. doi: 10.1530/JOE-15-0341. Epub 2015 Sep 28. Review.

14.

Thyroid gland: TSHR mutations and subclinical congenital hypothyroidism.

Schoenmakers N, Chatterjee VK.

Nat Rev Endocrinol. 2015 May;11(5):258-9. doi: 10.1038/nrendo.2015.27. Epub 2015 Feb 24. No abstract available.

PMID:
25707783
15.

An approach to quantifying abnormalities in energy expenditure and lean mass in metabolic disease.

Watson LP, Raymond-Barker P, Moran C, Schoenmakers N, Mitchell C, Bluck L, Chatterjee VK, Savage DB, Murgatroyd PR.

Eur J Clin Nutr. 2014 Feb;68(2):234-40. doi: 10.1038/ejcn.2013.237. Epub 2013 Nov 27.

16.

Thyroid in 2012: Advances in thyroid development, hormone action and neoplasia.

Chatterjee VK.

Nat Rev Endocrinol. 2013 Feb;9(2):74-6. doi: 10.1038/nrendo.2012.253. Epub 2013 Jan 8. Review.

PMID:
23296175
17.

Thyroid dyshormonogenesis is mainly caused by TPO mutations in consanguineous community.

Cangul H, Aycan Z, Olivera-Nappa A, Saglam H, Schoenmakers NA, Boelaert K, Cetinkaya S, Tarim O, Bober E, Darendeliler F, Bas V, Demir K, Aydin BK, Kendall M, Cole T, Högler W, Chatterjee VK, Barrett TG, Maher ER.

Clin Endocrinol (Oxf). 2013 Aug;79(2):275-81. doi: 10.1111/cen.12127. Epub 2013 May 6.

PMID:
23236987
18.

Quality of life in European patients with Addison's disease: validity of the disease-specific questionnaire AddiQoL.

Øksnes M, Bensing S, Hulting AL, Kämpe O, Hackemann A, Meyer G, Badenhoop K, Betterle C, Parolo A, Giordano R, Falorni A, Papierska L, Jeske W, Kasperlik-Zaluska AA, Chatterjee VK, Husebye ES, Løvås K.

J Clin Endocrinol Metab. 2012 Feb;97(2):568-76. doi: 10.1210/jc.2011-1901. Epub 2011 Nov 16.

19.

What should be done when thyroid function tests do not make sense?

Gurnell M, Halsall DJ, Chatterjee VK.

Clin Endocrinol (Oxf). 2011 Jun;74(6):673-8. doi: 10.1111/j.1365-2265.2011.04023.x.

20.

Immunoglobulin interference in serum follicle-stimulating hormone assays: autoimmune and heterophilic antibody interference.

Webster R, Fahie-Wilson M, Barker P, Chatterjee VK, Halsall DJ.

Ann Clin Biochem. 2010 Jul;47(Pt 4):386-9. doi: 10.1258/acb.2010.010044. Epub 2010 May 28.

PMID:
20511373
21.

Maternal isodisomy for chromosome 9 causing homozygosity for a novel FOXE1 mutation in syndromic congenital hypothyroidism.

Castanet M, Mallya U, Agostini M, Schoenmakers E, Mitchell C, Demuth S, Raymond FL, Schwabe J, Gurnell M, Chatterjee VK.

J Clin Endocrinol Metab. 2010 Aug;95(8):4031-6. doi: 10.1210/jc.2010-0275. Epub 2010 May 19.

PMID:
20484477
22.

Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC.

Rubio-Cabezas O, Puri V, Murano I, Saudek V, Semple RK, Dash S, Hyden CS, Bottomley W, Vigouroux C, Magré J, Raymond-Barker P, Murgatroyd PR, Chawla A, Skepper JN, Chatterjee VK, Suliman S, Patch AM, Agarwal AK, Garg A, Barroso I, Cinti S, Czech MP, Argente J, O'Rahilly S, Savage DB; LD Screening Consortium.

EMBO Mol Med. 2009 Aug;1(5):280-7. doi: 10.1002/emmm.200900037.

23.

Development of a disease-specific quality of life questionnaire in Addison's disease.

Løvås K, Curran S, Oksnes M, Husebye ES, Huppert FA, Chatterjee VK.

J Clin Endocrinol Metab. 2010 Feb;95(2):545-51. doi: 10.1210/jc.2009-1711. Epub 2009 Dec 16.

PMID:
20016050
24.

Interference from heterophilic antibodies in TSH assays.

Halsall DJ, English E, Chatterjee VK.

Ann Clin Biochem. 2009 Jul;46(Pt 4):345-6. doi: 10.1258/acb.2009.009024. Epub 2009 Jun 1. No abstract available.

PMID:
19487413
25.

Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone.

Løvås K, Gjesdal CG, Christensen M, Wolff AB, Almås B, Svartberg J, Fougner KJ, Syversen U, Bollerslev J, Falch JA, Hunt PJ, Chatterjee VK, Husebye ES.

Eur J Endocrinol. 2009 Jun;160(6):993-1002. doi: 10.1530/EJE-08-0880. Epub 2009 Mar 12.

PMID:
19282465
26.

Familial dysalbuminemic hyperthyroxinemia: a persistent diagnostic challenge.

Cartwright D, O'Shea P, Rajanayagam O, Agostini M, Barker P, Moran C, Macchia E, Pinchera A, John R, Agha A, Ross HA, Chatterjee VK, Halsall DJ.

Clin Chem. 2009 May;55(5):1044-6. doi: 10.1373/clinchem.2008.120303. Epub 2009 Mar 12. No abstract available.

27.

A novel CYP11B2 gene mutation in an Asian family with aldosterone synthase deficiency.

Løvås K, McFarlane I, Nguyen HH, Curran S, Schwabe J, Halsall D, Bernhardt R, Wallace AM, Chatterjee VK.

J Clin Endocrinol Metab. 2009 Mar;94(3):914-9. doi: 10.1210/jc.2008-1524. Epub 2008 Dec 30.

PMID:
19116236
28.

Augmentation index in resistance to thyroid hormone (RTH).

Owen PJ, Chatterjee VK, John R, Halsall D, Lazarus JH.

Clin Endocrinol (Oxf). 2009 Apr;70(4):650-4. doi: 10.1111/j.1365-2265.2008.03422.x. Epub 2008 Sep 17.

PMID:
18803680
29.

Nuclear receptors and human disease: resistance to thyroid hormone and lipodystrophic insulin resistance.

Chatterjee VK.

Ann Endocrinol (Paris). 2008 Apr;69(2):103-6. doi: 10.1016/j.ando.2008.02.005. Epub 2008 Apr 21. Review. No abstract available.

PMID:
18430406
30.

Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial.

Gurnell EM, Hunt PJ, Curran SE, Conway CL, Pullenayegum EM, Huppert FA, Compston JE, Herbert J, Chatterjee VK.

J Clin Endocrinol Metab. 2008 Feb;93(2):400-9. Epub 2007 Nov 13.

31.

A clinical approach to severe insulin resistance.

Savage DB, Semple RK, Chatterjee VKK, Wales JKH, Ross RJM, O'Rahilly S.

Endocr Dev. 2007;11:122-132. doi: 10.1159/000111067. Review.

PMID:
17986832
32.

International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.

Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W.

Pharmacol Rev. 2006 Dec;58(4):726-41. Review.

PMID:
17132851
33.

Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor gamma function (P465L PPARgamma) in mice.

Gray SL, Nora ED, Grosse J, Manieri M, Stoeger T, Medina-Gomez G, Burling K, Wattler S, Russ A, Yeo GS, Chatterjee VK, O'Rahilly S, Voshol PJ, Cinti S, Vidal-Puig A.

Diabetes. 2006 Oct;55(10):2669-77.

34.

Macro thyrotropin-IgG complex causes factitious increases in thyroid-stimulating hormone screening tests in a neonate and mother.

Halsall DJ, Fahie-Wilson MN, Hall SK, Barker P, Anderson J, Gama R, Chatterjee VK.

Clin Chem. 2006 Oct;52(10):1968-9; author reply 1969-70. No abstract available.

35.

Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype.

Manji N, Carr-Smith JD, Boelaert K, Allahabadia A, Armitage M, Chatterjee VK, Lazarus JH, Pearce SH, Vaidya B, Gough SC, Franklyn JA.

J Clin Endocrinol Metab. 2006 Dec;91(12):4873-80. Epub 2006 Sep 12.

PMID:
16968788
36.

A novel missense mutation in human TTF-2 (FKHL15) gene associated with congenital hypothyroidism but not athyreosis.

Baris I, Arisoy AE, Smith A, Agostini M, Mitchell CS, Park SM, Halefoglu AM, Zengin E, Chatterjee VK, Battaloglu E.

J Clin Endocrinol Metab. 2006 Oct;91(10):4183-7. Epub 2006 Aug 1.

PMID:
16882747
37.

Elevated plasma adiponectin in humans with genetically defective insulin receptors.

Semple RK, Soos MA, Luan J, Mitchell CS, Wilson JC, Gurnell M, Cochran EK, Gorden P, Chatterjee VK, Wareham NJ, O'Rahilly S.

J Clin Endocrinol Metab. 2006 Aug;91(8):3219-23. Epub 2006 May 16.

PMID:
16705075
38.

PPAR gamma and human metabolic disease.

Semple RK, Chatterjee VK, O'Rahilly S.

J Clin Invest. 2006 Mar;116(3):581-9. Review.

39.

Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone.

Teresi RE, Shaiu CW, Chen CS, Chatterjee VK, Waite KA, Eng C.

Int J Cancer. 2006 May 15;118(10):2390-8.

40.

Dehydroepiandrosterone replacement in patients with Addison's disease has a bimodal effect on regulatory (CD4+CD25hi and CD4+FoxP3+) T cells.

Coles AJ, Thompson S, Cox AL, Curran S, Gurnell EM, Chatterjee VK.

Eur J Immunol. 2005 Dec;35(12):3694-703.

41.

Genetics of congenital hypothyroidism.

Park SM, Chatterjee VK.

J Med Genet. 2005 May;42(5):379-89. Review.

42.

Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma.

Risérus U, Tan GD, Fielding BA, Neville MJ, Currie J, Savage DB, Chatterjee VK, Frayn KN, O'Rahilly S, Karpe F.

Diabetes. 2005 May;54(5):1379-84.

43.

A dominant negative human peroxisome proliferator-activated receptor (PPAR){alpha} is a constitutive transcriptional corepressor and inhibits signaling through all PPAR isoforms.

Semple RK, Meirhaeghe A, Vidal-Puig AJ, Schwabe JW, Wiggins D, Gibbons GF, Gurnell M, Chatterjee VK, O'Rahilly S.

Endocrinology. 2005 Apr;146(4):1871-82. Epub 2005 Jan 20.

PMID:
15661858
44.

Energy expenditure and adaptive responses to an acute hypercaloric fat load in humans with lipodystrophy.

Savage DB, Murgatroyd PR, Chatterjee VK, O'Rahilly S.

J Clin Endocrinol Metab. 2005 Mar;90(3):1446-52. Epub 2004 Dec 21.

PMID:
15613417
45.
46.

PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase.

Verrier E, Wang L, Wadham C, Albanese N, Hahn C, Gamble JR, Chatterjee VK, Vadas MA, Xia P.

Circ Res. 2004 Jun 11;94(11):1515-22. Epub 2004 Apr 29.

PMID:
15117825
47.
48.

Focused parathyroid surgery with intraoperative parathyroid hormone measurement as a day-case procedure.

Gurnell EM, Thomas SK, McFarlane I, Munday I, Balan KK, Berman L, Chatterjee VK, Wishart GC.

Br J Surg. 2004 Jan;91(1):78-82.

PMID:
14716798
49.

Does peroxisome proliferator-activated receptor gamma genotype (Pro12ala) modify the association of physical activity and dietary fat with fasting insulin level?

Franks PW, Luan J, Browne PO, Harding AH, O'Rahilly S, Chatterjee VK, Wareham NJ.

Metabolism. 2004 Jan;53(1):11-6.

PMID:
14681835
50.

Supplemental Content

Loading ...
Support Center